Our Mission

To become a world leader in developing targeted therapies for hepatologic diseases and viral infections, including CHB, nonalcoholic steatohepatitis (NASH), and hepatocellular carcinoma (HCC) and COVID-19, which collectively affect hundreds of millions of people.

Pipeline

With Aligos’ extensive expertise and experience in developing therapeutics for chronic liver diseases, we are building a robust pipeline of best-in-class drug candidates focused on developing curative therapies for chronic hepatitis B and delivering transformative treatments in other areas of liver disease.

Management Team

Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat.

Our Mission

To become a world leader in developing targeted therapies for hepatologic diseases and viral infections, including CHB, nonalcoholic steatohepatitis (NASH), and hepatocellular carcinoma (HCC) and COVID-19, which collectively affect hundreds of millions of people.

Join the Aligos TeamJoin our growing team in developing targeted therapies for liver diseases like chronic hepatitis B nd NASH.

Join the Aligos Team

Join our growing team in developing targeted therapies for liver diseases like chronic hepatitis B nd NASH.

Scientific Overview

Aligos’ lead programs in CHB comprise oligonucleotide and small molecule candidates that target three clinically validated mechanisms that may contribute to a functional cure. Aligos harnesses its highly experienced scientific and management teams to advance its purpose-built pipeline.

Coronavirus
Coronavirus

COVID-19 Update

As a healthcare company with longstanding experience in viral therapeutic development, we have a responsibility to determine whether our technologies may yield promising therapeutic candidates for COVID-19.

To this end, Aligos has expanded an existing license agreement with Luxna Biotech Inc., Ltd. granting Aligos exclusive rights to use Luxna’s innovative modified nucleic acid technology to target the genomes of certain viruses, including SARS-CoV-2, the virus causing COVID-19.

Additionally, Aligos has entered into a collaboration and license agreement with KU Leuven’s Centre for Drug Design and Discovery (CD3) and the Rega Institute for Medical Research, to develop a coronavirus protease inhibitor as a potential therapeutic candidate.

Aligos will provide updates regarding progress in these areas as appropriate.

US Office

1 Corporate Dr., 2nd Floor
South San Francisco, CA 94080
  info@aligos.com

European Office

Gaston Geenslaan 1 / (Building 3)
3001 Leuven, Belgium
  info@aligos.com

Quick Links

About Us
Management
Press & Publications
Pipeline
Partners

Follow Us

About Us

Jack B. Nielsen

Jack B. Nielsen has served as Chairman of the board of directors of Aligos since August 2018. Jack has been a Managing Director at Vivo Capital LLC, since 2017. From 2001 to February 2017, Jack worked within the Novo A/S organization and its venture activities in several roles, most recently being employed as a Senior Partner based in Copenhagen, Denmark. From 2006 to 2012, Jack was employed as a Partner at Novo Ventures (US) Inc. in San Francisco. Jack currently serves on the Board of Directors of Crinetics Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Harmony Biosciences, Inc, and Maculogix, Inc. He previously served on the board of directors of the following public companies: Merus, N.V., Apollo Endosurgery, and Akebia Therapeutics. Jack received a M.Sc. in Chemical Engineering from the Technical University of Denmark, and a Masters in Management of Technology from Center for Technology, Economics and Management, Technical University of Denmark.

Jack B. Nielsen

Jack B. Nielsen has served as Chairman of the board of directors of Aligos since August 2018. Jack has been a Managing Director at Vivo Capital LLC, since 2017. From 2001 to February 2017, Jack worked within the Novo A/S organization and its venture activities in several roles, most recently being employed as a Senior Partner based in Copenhagen, Denmark. From 2006 to 2012, Jack was employed as a Partner at Novo Ventures (US) Inc. in San Francisco. Jack currently serves on the Board of Directors of Crinetics Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Harmony Biosciences, Inc, and Maculogix, Inc. He previously served on the board of directors of the following public companies: Merus, N.V., Apollo Endosurgery, and Akebia Therapeutics. Jack received a M.Sc. in Chemical Engineering from the Technical University of Denmark, and a Masters in Management of Technology from Center for Technology, Economics and Management, Technical University of Denmark.

Jack B. Nielsen

Jack B. Nielsen has served as Chairman of the board of directors of Aligos since August 2018. Jack has been a Managing Director at Vivo Capital LLC, since 2017. From 2001 to February 2017, Jack worked within the Novo A/S organization and its venture activities in several roles, most recently being employed as a Senior Partner based in Copenhagen, Denmark. From 2006 to 2012, Jack was employed as a Partner at Novo Ventures (US) Inc. in San Francisco. Jack currently serves on the Board of Directors of Crinetics Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Harmony Biosciences, Inc, and Maculogix, Inc. He previously served on the board of directors of the following public companies: Merus, N.V., Apollo Endosurgery, and Akebia Therapeutics. Jack received a M.Sc. in Chemical Engineering from the Technical University of Denmark, and a Masters in Management of Technology from Center for Technology, Economics and Management, Technical University of Denmark.

Lawrence Blatt, Ph.D., MBA

Chief Executive Officer

• Global Infectious Diseases Therapeutic Area Head – Janssen
• Co-Founder, Chief Executive Officer – Alios BioPharma
• Chief Scientific Officer – InterMune
• Senior Vice President, Research – Ribozyme/SIRNA
• Senior Director, Interferon Research – Amgen

Lucinda Quan, J.D.

Executive Vice President
Chief Business Officer & General Counsel

• Global Infectious Diseases Therapeutic Area Head – Janssen
• Co-Founder, Chief Executive Officer – Alios BioPharma
• Chief Scientific Officer – InterMune
• Senior Vice President, Research – Ribozyme/SIRNA
• Senior Director, Interferon Research – Amgen

Lawrence Blatt, Ph.D., MBA

Chief Executive Officer

• Global Infectious Diseases Therapeutic Area Head – Janssen
• Co-Founder, Chief Executive Officer – Alios BioPharma
• Chief Scientific Officer – InterMune
• Senior Vice President, Research – Ribozyme/SIRNA
• Senior Director, Interferon Research – Amgen

COVID-19 Presentation

Aligos Therapeutics

ALIGOS - San Francisco

US Office

1 Corporate Dr., 2nd Floor
South San Francisco, CA 94080
 info@aligos.com

ALIGOS - Leuven

European Office

Gaston Geenslaan 1 / (Building 3)
3001 Leuven, Belgium
 info@aligos.com